Trial Profile
Efficacy and safety of ombitasvir, paritaprevir, ritonavir +/- dasabuvir +/- ribavirin in patients with chronic hepatitis c virus infection
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 20 Jan 2018
Price :
$35
*
At a glance
- Drugs Ombitasvir/paritaprevir/ritonavir (Primary) ; Dasabuvir; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions; Expanded access; Therapeutic Use
- 20 Jan 2018 New trial record